Barclays Maintains an 'Overweight/Best Idea' on Pacira Pharmaceuticals (PCRX); It's Early, But Off To Good Start
Tweet Send to a Friend
Barclays maintains an 'Overweight' on Pacira Pharmaceuticals (NASDAQ: PCRX) price target of $19.00 (from $12.00).
Analyst, Douglas D. Tsao ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Analyst, Douglas D. Tsao ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
